1. Volume 377, Issue 9773, Pages 1256-1263 (April 2011)
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial 
Prof Paul D Griffiths, MD, Anna Stanton, RN, Erin McCarrell, MSc, Colette Smith, PhD, Mohamed Osman, PhD, Mark Harber, FRCP, Andrew Davenport, FRCP, Gareth Jones, MRCP, David C Wheeler, FRCP, James O'Beirne, MRCP, Douglas Thorburn, FRCP, David Patch, FRCP, Claire E Atkinson, MSc, Sylvie Pichon, MSc, Paul Sweny, FRCP, Marisa Lanzman, MRPharmS, Elizabeth Woodford, Emily Rothwell, RGN, Natasha Old, BA, Ruth Kinyanjui, RN, Tanzina Haque, FRCPath, Sowsan Atabani, MRCPath, Suzanne Luck, MBChB, Steven Prideaux, BSc, Richard SB Milne, PhD, Prof Vincent C Emery, PhD, Prof Andrew K Burroughs, FRCP 
The Lancet 
Volume 377, Issue 9773, Pages (April 2011)
DOI: /S (11)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile at the time of analysis
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2
Geometric mean (95% CI) antibody titres measured by glycoprotein-B enzyme-linked immunoassay
(A) Seronegative recipients. (B) Seropositive recipients. Tx indicates the geometric mean titres found at the time of transplantation.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

4. Figure 3
Inverse correlation of titre of antibodies against glycoprotein B present at the time of transplantation with duration of viraemia after transplantation
Only patients with viraemia at any time were selected for this analysis. D−=cytomegalovirus seronegative donor. R−=cytomegalovirus seronegative recipient. D+=cytomegalovirus seropositive donor. R+=cytomegalovirus seropositive recipient.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

5. Figure 4
Proportion of days that patients in the three subgroups at risk of CMV infection spent with viraemia or received antiviral treatment
A,B, and C show the duration of viraemia. D,E, and F show the duration of antiretroviral therapy. D+R−, D+R+, and D−R+ are three groups at risk of primary infection, reinfection, and reactivation, respectively. The numbers below each column indicate the number of patients with viraemia (or treatment) divided by the number in the subgroup. Note the different values on the Y-axes of panels A and D compared with panels B, C, E, and F. D−=cytomegalovirus seronegative donor. R−=cytomegalovirus seronegative recipient. D+=cytomegalovirus seropositive donor. R+=cytomegalovirus seropositive recipient.
The Lancet  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions